In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
The Indian Institute of Management, Bangalore, has called off its plan to start full-time operations in Singapore. Instead, it is exploring tie-ups with institutes in Singapore to offer Executive MBA (EMBA) programmes.
Tata Motors may soon set up a car manufacturing unit in Egypt, North Africa. The car major is said to have held talks with an eight-member high-level delegation from Egypt.
Working students, shortlisted by the Indian Institutes of Management for admission to this year's batch, are on the tenterhooks since many of them have put in their papers and are serving notice periods.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
A state-funded university, it may pump in money into the stock market through its corpus fund of over Rs 100 crore.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
A programme to train the judges has been proposed where they would be attending a two-week advanced executive programme in management of cases, at the Harvard Business School.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
Amgen, the world's largest biotechnology company, has entered India by opening a wholly owned subsidiary Amgen Technology in Mumbai.
The Indian School of Business (ISB) Hyderabad, for instance, will hike the fee from Rs 13.65 lakh (Rs 1.365 million) to Rs 14 lakh (Rs 1.4 million) for its flagship one-year management programme.
The University of Adelaide, Australia, will soon set up India's first wine institute at Narayangaon, 80 km from Pune, Maharashtra, in association with India's largest wine making company, Champagne Indage.
Mumbai-based Advanced Enzyme Technologies Ltd, the largest manufacturer of enzymes in the country, will invest Rs 115 crore to set up three biotech production facilities.
To date, when an Indian engineer wants to practice abroad, he needs to fulfill certain requirements.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
Spectrum Retail Mart, a retail chain of medical stores and fast moving consumer goods, has set up shop in Mumbai with an initial investment of over Rs 90 crore (Rs 900 million).
While the premier IIMs Ahmedabad, Bangalore and Calcutta have yet to conclude the final placements, last year's (2006) figures reveal that the average salaries hovered below Rs 10 lakh.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances